Literature DB >> 6971585

IgE antibodies to bacteria in patients with bronchial asthma.

R Pauwels, G Verschraegen, M van der Straeten.   

Abstract

Bacterial respiratory infections, especially with Haemophilus influenzae and Streptococcus pneumoniae, are frequently associated with an increase of airways obstruction in patients with bronchial asthma. The possible involvement of immediate hypersensitivity in this phenomenon was studied. IgE antibodies to Haemophilus influenzae (HI) and Streptococcus pneumoniae (SPn) were investigated in the serum of 190 adult patients with bronchial asthma. The IgE antibodies were measured using a solid phase radioimmunoassay method. Living bacteria were used as solid phase. A correction of the non-specific binding of IgE was necessary. IgE antibodies to one or both bacteria were present in 55 of the 190 patients (29%). Eighteen patients were sensitive to HI, 33 to SPn and four to both bacteria. Significantly more IgE antibodies to bacteria were found in patients with demonstrable IgE antibodies to various inhalant allergens. However, the IgE antibodies to one or both bacteria were also present in 22% of patients with no other demonstrable IgE mediated hypersensitivity. The total serum IgE level in patients with IgE antibodies to bacteria was not significantly higher than in patients without hypersensitivity to these bacteria. From these data we concluded that immediate hypersensitivity to bacteria may play a role in the infectious exacerbations of bronchial asthma.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6971585     DOI: 10.1111/j.1398-9995.1980.tb02019.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  11 in total

Review 1.  Clinical significance of anti-IgE autoantibodies and immune complexes containing IgE.

Authors:  C G Magnusson; S G Johansson
Journal:  Clin Rev Allergy       Date:  1989

2.  Serum antibodies to Legionella agents in bronchial asthma.

Authors:  S Beer; I Boldur; R Kazak; S Avidan; Y Kannai
Journal:  Arch Dis Child       Date:  1985-03       Impact factor: 3.791

Review 3.  Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review.

Authors:  S Sethi; T F Murphy
Journal:  Clin Microbiol Rev       Date:  2001-04       Impact factor: 26.132

Review 4.  Mycoplasma pneumoniae and its role in asthma.

Authors:  Nazima Nisar; Randeep Guleria; Sanjay Kumar; Tirlok Chand Chawla; Nihar Ranjan Biswas
Journal:  Postgrad Med J       Date:  2007-02       Impact factor: 2.401

5.  Intelligent medical diagnostics via molecular logic.

Authors:  Tania Konry; David R Walt
Journal:  J Am Chem Soc       Date:  2009-09-23       Impact factor: 15.419

6.  Effects of Staphylococcus aureus cell wall products (teichoic acid, peptidoglycan) and enterotoxin B on immunoglobulin (IgE, IgA, IgG) synthesis and CD23 expression in patients with atopic dermatitis.

Authors:  K Neuber; W König
Journal:  Immunology       Date:  1992-01       Impact factor: 7.397

7.  Microsphere-based rolling circle amplification microarray for the detection of DNA and proteins in a single assay.

Authors:  Tania Konry; Ryan B Hayman; David R Walt
Journal:  Anal Chem       Date:  2009-07-15       Impact factor: 6.986

8.  Haemophilus influenzae and smoking-related obstructive airways disease.

Authors:  Diana C Otczyk; Robert L Clancy; Allan W Cripps
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2011-06-16

9.  Anti-bacterial IgE in the antibody responses of house dust mite allergic children convalescent from asthma exacerbation.

Authors:  B J Hales; A C Martin; L J Pearce; K Rueter; G Zhang; S-K Khoo; C M Hayden; J Bizzintino; P McMinn; G C Geelhoed; W-M Lee; J Goldblatt; I A Laing; P N LeSouëf; W R Thomas
Journal:  Clin Exp Allergy       Date:  2009-04-17       Impact factor: 5.018

Review 10.  Microorganisms and exacerbation of chronic obstructive pulmonary diseases: pathophysiological mechanisms.

Authors:  P Clementsen; K S Kristensen; S Norn
Journal:  Allergy       Date:  1992-06       Impact factor: 13.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.